Antithrombotic strategy | NCB (overall) (WF of 1.0) | NCB (overall) (WF of 1.5) | NCB (overall) (WF of 2.0) |
---|---|---|---|
Any OACs vs. No OACs | |||
CHA2DS2-VASc of 0–1 | 0.04 (0.04 to 0.05) | -0.37 (-0.79 to 0.05) | -0.78 (-1.62 to 0.05) |
CHA2DS2-VASc of 2 | -1.78 (-2.07 to -1.49) | -2.41 (-3.34 to -1.48) | -3.04 (-4.61 to -1.46) |
CHA2DS2-VASc of ≥ 3 | 0.52 (0.33 to 0.73) | 0.04 (-0.31 to 0.39) | -0.44 (-1.34 to 0.46) |
Warfarin vs. No OACs | |||
CHA2DS2-VASc of 0–1 | -0.17 (-0.28 to -0.05) | -0.67 (-1.27 to -0.07) | -1.18 (-2.26 to -0.09) |
CHA2DS2-VASc of 2 | -1.97 (-2.29 to -1.65) | -2.69 (-3.68 to -1.70) | -3.41 (-5.07 to -1.75) |
CHA2DS2-VASc of ≥ 3 | 0.38 (0.19 to 0.58) | -0.13 (-0.49 to 0.23) | -0.65 (-1.57 to 0.27) |
DOACs vs. No OACs | |||
CHA2DS2-VASc of 0–1 | 1.18 (0.70 to 1.66) | 1.25 (0.92 to 1.59) | 1.33 (1.14 to 1.52) |
CHA2DS2-VASc of 2 | 0.31 (-1.03 to 1.64) | 0.73 (-0.13 to 1.59) | 1.15 (0.77 to 1.54) |
CHA2DS2-VASc of ≥ 3 | 2.19 (1.82 to 2.57) | 2.08 (0.73 to 3.42) | 1.96 (-0.36 to 4.27) |
Warfarin (TTR ≥ 65%) vs. No OACs | |||
CHA2DS2-VASc of 0–1 | -0.33 (-1.31 to 0.64) | -1.02 (-2.86 to 0.82) | -1.70 (-4.41 to 1.01) |
CHA2DS2-VASc of 2 | -0.63 (-1.12 to -0.13) | -0.97 (-2.24 to 0.31) | -1.31 (-3.36 to 0.75) |
CHA2DS2-VASc of ≥ 3 | 2.63 (2.52 to 2.73) | 2.72 (2.22 to 3.23) | 2.82 (1.72 to 3.93) |
DOACs versus Warfarin | |||
CHA2DS2-VASc of 0–1 | 1.35 (0.80 to 1.90) | 1.93 (0.92 to 2.93) | 2.50 (1.03 to 3.97) |
CHA2DS2-VASc of 2 | 2.28 (0.96 to 3.60) | 3.42 (2.57 to 4.28) | 4.56 (4.18 to 4.95) |
CHA2DS2-VASc of ≥ 3 | 1.81 (1.10 to 2.53) | 2.21 (0.60 to 3.82) | 2.60 (0.10 to 5.11) |
DOACs versus Warfarin (TTR ≥ 65%) | |||
CHA2DS2-VASc of 0–1 | 1.51 (-0.20 to 3.23) | 2.27 (-0.30 to 4.84) | 3.03 (-0.40 to 6.46) |
CHA2DS2-VASc of 2 | 0.93 (-0.12 to 1.98) | 1.69 (1.25 to 2.14) | 2.46 (2.29 to 2.63) |
CHA2DS2-VASc of ≥ 3 | -0.43 (-1.19 to 0.33) | -0.65 (-2.34 to 1.04) | -0.87 (-3.48 to 1.75) |